# Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

> **NCT07349225** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Second Affiliated Hospital of Dalian Medical University** · enrollment: 46 (estimated)

## Conditions studied

- ES-SCLC

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **RADIATION:** Targeted Radiation Therapy

## Key facts

- **NCT ID:** NCT07349225
- **Lead sponsor:** The Second Affiliated Hospital of Dalian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-28
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349225, "Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07349225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*